Cargando…
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
Heart failure (HF) is a clinical syndrome characterized by the presence of dyspnea or limited exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high prevalence, it is a major health and economic burden worldwide. Several mechanisms are involved in the pathoph...
Autores principales: | Pascual-Figal, Domingo, Bayés-Genis, Antoni, Beltrán-Troncoso, Paola, Caravaca-Pérez, Pedro, Conde-Martel, Alicia, Crespo-Leiro, Maria G., Delgado, Juan F., Díez, Javier, Formiga, Francesc, Manito, Nicolás |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631913/ https://www.ncbi.nlm.nih.gov/pubmed/34859070 http://dx.doi.org/10.3389/fcvm.2021.754499 |
Ejemplares similares
-
Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
por: Codina, Pau, et al.
Publicado: (2022) -
Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
por: Lupón, Josep, et al.
Publicado: (2021) -
Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach
por: Iborra-Egea, Oriol, et al.
Publicado: (2017) -
Rationale and design of TRANSITION: a randomized trial of pre‐discharge vs. post‐discharge initiation of sacubitril/valsartan
por: Pascual‐Figal, Domingo, et al.
Publicado: (2017) -
Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure
por: Witte, Klaus K., et al.
Publicado: (2022)